Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.